About IntelliCell BioSciences, Inc.
IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC). VFC is also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. VFC type cells are in research projects and in clinical trials around the world.
IntelliCell was formed to take a leading role and harmonize the interests of all the stakeholder communities in the rapidly expanding regenerative medicine field. IntelliCell is fully committed to an ethical and supportive role in providing the tools to physicians and patients to fight some of the most serious disease conditions with very high levels of unmet clinical needs.
The VFC cells that are being processed by IntelliCell are known as autologous cells. That is the donor of cells and the recipient of the cells are the same person. IntelliCell is unique as it does not use any chemicals or biological agents such as collagenese in its proprietary and patent pending process. The Company has developed a novel ultrasound process to assist the laboratory in the preparation of the VFC cells. In a process similar to the acquisition of autologous stem cells from bone marrow aspirate, the IntelliCell VFC cells are being given to physicians working in the field of regenerative medicine.
Management
Dr. Steven Victor, Chairman and CEO
Dr. Steven Victor, founder and CEO of IntelliCell has been at the forefront of clinical product and process development for over 20 years. The patent pending process that Dr. Victor has developed for IntelliCell™ has been in research for over 4 years. In addition to developing clinical products that are used nationally and internationally in the medical aesthetics field, Dr. Victor is a practicing dermatologist in New York City. Dr. Victor's interest in regenerative medicine began well over a decade ago with the clinical use of autologous fibroblast cells for the purpose of dermal regeneration. Dr. Victor received his medical degree from New York college and a Bachelor of Arts degree from New York University and has held hospital based teaching positions. He has been a sought after national figure for teaching physicians new clinical techniques worldwide for over 20 years. Dr. Victor has also been featured in national and local media as a clinical subject matter expert in regenerative medicine, medical aesthetics, and dermatology.
Robert J. Sexauer, Executive Vice President Clinical Development
Mr. Sexauer has been in the medical technology industry since 1979 and has served in a series of executive corporate positions with a specialization in international clinical, corporate and product development. In 2006, he formed InterMark Associates Ltd., a London based consulting organization focused on the regenerative medicine industry. Among projects undertaken included a turn around as CEO of a California based nanotechnology company that resulted in a settlement with the SEC and redirection of the company's business. Also, Mr. Sexauer directed the first ever in human clinical trial utilizing two autologous cell lines for regenerative medicine. Prior to InterMark, he was responsible for the corporate launch of Isolagen Europe, Ltd. Isolagen developed a pioneering regenerative medicine autologous cellular application for the anti-aging and dermal regeneration market.
Mr. Sexauer has worked extensively outside the United States while also directing mergers and acquisitions at the corporate level and has been a featured guest lecturer at DePaul University in the graduate school of International Marketing. He has also been a featured speaker at national conferences in the medical and information technology sectors addressing market conditions and valuations for mergers and acquisitions.
Anna Rhodes, Executive VP Operations
Anna Rhodes, our Executive Vice President of Operations, has been actively involved in the cosmetic and cosmeceuticals industries for over 9 years. From 2001 through 2009, Ms. Rhodes held various executive sales positions with Victor Cosmeceuticals, Inc. and Victor Products Inc., with primary responsibility for the development of many of the marketing and collateral materials, formulations and training materials for new product launches as well as managing international distribution. Prior to 2001, Ms. Rhodes held various sales positions in the high fashion industry with companies including Calvin Klein, Agnona and Michael Kors. She was a Magnum Cum Laude graduate of the University of Texas with a Bachelor of Science degree in Business Administration.
Sarah R. Young, Quality Assurance Manager
Prior to joing IntelliCell Ms. Young managed the QA departments for RTI Biologics, Inc. and Southeast Tissue Alliance, Inc. She is an experienced QA Director with nine years of experience working in high-volume manufacturing settings of human cellular and tissue-based products (HCT/Ps) and medical device products regulated under stringent good manufacturing practices (cGTPs/cGMPs) by the US Food and Drug Administration (FDA) as well as state specific statutes/regulations. She has held a Certified Tissue Bank Specialist certification from the tissue banking industry's quality standards setting organization, the American Association of Tissue Banks (AATB), since 2001, where she has also been a member of AATB's Quality Assurance Committee helping establish quality standards, guidances and providing training to the industry since 2005. She has experience with building new quality programs for partner agencies/satellite offices and training staff, writing standard operating procedures, engineering/designing validation protocols (R&D product development, processing, sterilization/decontamination, labeling, implementing effective corrective and preventive action systems, managing complaints and recalls, auditing and site inspections/qualifications, medical records management and healthcare experience, as well as prior experience with FDA.
Board of Directors
- Leonard Mazur, COO Triax, Interim COO of IntelliCell BioSciences
- Steven Victor MD
- Myron Holubiak, Director, Chair of the Nominating and Governance Committee
Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation.
- Michael J. Hershman
Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.
Medical Board of Advisors
- Dr. James Andrews, The Andrews Institute
- Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
- Dr. Peter Bruno, Internist, New York City
- Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
- Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
- Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
- Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
- Dr. Alberto Goldman, Plastic Surgeon, Brazil
- Dr. Joshua Hackel, The Andrews Institute
- Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
- Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
- Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
- Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore
- Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
- Mr. Kevin Wilk, PT, DPT The Andrews Institute
Corporate Board of Advisors
- John A. Schneider, Former Managing Director of Allen & Co.